{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:54:26Z","timestamp":1791942866796,"version":"4.3.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Misfolding and aggregation of the neuronal protein alpha-synuclein (aSyn) has been identified as a hallmark of Parkinson\u2019s disease (PD) pathology and other synucleinopathies. Preventing formation of intracellular aSyn accumulations constitutes a therapeutic strategy against disease development. We recently reported on a new type of affinity protein, denoted <jats:italic>Sequestrin<\/jats:italic>, aimed for efficient and stable interactions with aggregation-prone amyloidogenic proteins and peptides. Upon binding, sequestrins interact with the aggregation-prone peptide and form a stabilizing four-stranded beta sheet with similarities to the beta sheet rich structures seen in amyloid fibrils. Here, high-affinity aSyn-binding sequestrins were isolated from a large na\u00efve sequestrin library using phage display technology. The best binders demonstrated dissociation constant, K<jats:sub>D,<\/jats:sub> values in the 10 nM-range, and structural rearrangements in both the sequestrin and aSyn protein upon binding. Modelling using AlphaFold, followed by NMR spectroscopy suggested that the sequestrins bind an N-terminal region of aSyn that is critical for amyloidogenic aggregation. In an <jats:italic>in vitro<\/jats:italic> aggregation study, the sequestrins demonstrated complete inhibition of aSyn aggregation at equimolar concentrations, including the three familial mutants A30P, E46K, and A53T that are associated with Parkinson\u2019s disease and Lewy body dementia.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1574755","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T05:20:13Z","timestamp":1747372813000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Engineered sequestrins inhibit aggregation of pathogenic alpha-synuclein mutants"],"prefix":"10.3389","volume":"16","author":[{"given":"Linnea Charlotta","family":"Hjelm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Paslawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christofer","family":"Lendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri Flemming","family":"Svedmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00e5hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"L\u00f6fblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/35081564","article-title":"Alpha-synuclein and neurodegenerative diseases","volume":"2","author":"Goedert","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40035-017-0099-z","article-title":"Current understanding of the molecular mechanisms in Parkinson\u2019s disease: Targets for potential treatments","volume":"6","author":"Maiti","year":"2017","journal-title":"Transl Neurodegener"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front Public Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28941","article-title":"Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers","volume":"37","author":"Barba","year":"2022","journal-title":"Mov Disord"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-020-00368-6","article-title":"Initiation and propagation of alpha-synuclein aggregation in the nervous system","volume":"15","author":"Hijaz","year":"2020","journal-title":"Mol Neurodegener"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.5b13261","article-title":"X-ray Crystallographic Structure of Oligomers Formed by a Toxic beta-Hairpin Derived from alpha-Synuclein: Trimers and Higher-Order Oligomers","volume":"138","author":"Salveson","year":"2016","journal-title":"J Am Chem Soc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4648","article-title":"alpha-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B","volume":"20","author":"Ferreira","year":"2017","journal-title":"Nat Neurosci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"942313","DOI":"10.3389\/fneur.2022.942313","article-title":"Editorial: targeting alpha-synuclein in Parkinson\u2019s disease and multiple system atrophy","volume":"13","author":"Fellner","year":"2022","journal-title":"Front Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/jpd-240272","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-239901","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2023 update","volume":"13","author":"McFarthing","year":"2023","journal-title":"J Parkinsons Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"104582","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105543","DOI":"10.1016\/j.nbd.2021.105543","article-title":"ABBV-0805, a novel antibody selective for soluble aggregated alpha-synuclein, prolongs lifespan and prevents buildup of alpha-synuclein pathology in mouse models of Parkinson\u2019s disease","volume":"161","author":"Nordstrom","year":"2021","journal-title":"Neurobiol Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1994690","DOI":"10.1080\/19420862.2021.1994690","article-title":"Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies","volume":"13","author":"Fjord-Larsen","year":"2021","journal-title":"MAbs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03270-6","article-title":"Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/antib10020013","article-title":"Recent advances in the molecular design and applications of multispecific biotherapeutics","volume":"10","author":"Zhong","year":"2021","journal-title":"Antibod (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody molecules in biotechnological and medical applications","volume":"35","author":"Stahl","year":"2017","journal-title":"Trends Biotechnol"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot108401","article-title":"Selection of Affibody Molecules Using Staphylococcal Display","volume-title":"Advances in Phage Display Collection: A Laboratory Manual Second","author":"Lofblom","year":"2024"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot108399","article-title":"Selection of Affibody Molecules Using Phage Display","volume-title":"Advances in Phage Display Collection: A Laboratory Manual Second","author":"Hjelm","year":"2024"},{"key":"B26","article-title":"Selection of Affibody Molecules Using Escherichia coli Display","volume-title":"Advances in Phage Display Collection: A Laboratory Manual Second","author":"Dahlsson Leitao","year":"2024"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2209920","DOI":"10.1080\/19420862.2023.2209920","article-title":"Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis","volume":"15","author":"Klint","year":"2023","journal-title":"MAbs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzn028","article-title":"Engineering of a femtomolar affinity binding protein to human serum albumin","volume":"21","author":"Jonsson","year":"2008","journal-title":"Protein Eng Design Select"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad186","article-title":"Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment","volume":"189","author":"Gerdes","year":"2023","journal-title":"Br J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2006.09.013","article-title":"Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides","volume":"128","author":"Gronwall","year":"2007","journal-title":"J Biotechnol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711731105","article-title":"Stabilization of a beta-hairpin in monomeric Alzheimer\u2019s amyloid-beta peptide inhibits amyloid formation","volume":"105","author":"Hoyer","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jmb.2008.02.040","article-title":"Interaction of Alzheimer\u2019s A beta peptide with an engineered binding protein\u2013thermodynamics and kinetics of coupled folding-binding","volume":"378","author":"Hoyer","year":"2008","journal-title":"J Mol Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fnagi.2019.00064","article-title":"Affibody-mediated sequestration of amyloid beta demonstrates preventive efficacy in a transgenic Alzheimer\u2019s disease mouse model","volume":"11","author":"Boutajangout","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201500131","article-title":"A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity","volume":"10","author":"Lindberg","year":"2015","journal-title":"Biotechnol J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/ijms24010836","article-title":"Construction and validation of a new naive sequestrin library for directed evolution of binders against aggregation-prone peptides","volume":"24","author":"Hjelm","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2978-8_9","article-title":"Formation and characterization of alpha-synuclein oligomers","volume":"1345","author":"Paslawski","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821409116","article-title":"alpha-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson\u2019s disease patients","volume":"116","author":"Paslawski","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10858-009-9313-3","article-title":"3D J-resolved NMR spectroscopy for unstructured polypeptides: fast measurement of 3J HNH alpha coupling constants with outstanding spectral resolution","volume":"44","author":"Lendel","year":"2009","journal-title":"J Biomol NMR"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/prot.20449","article-title":"The CCPN data model for NMR spectroscopy: development of a software pipeline","volume":"59","author":"Vranken","year":"2005","journal-title":"Proteins"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/bf00175254","article-title":"A general enhancement scheme in heteronuclear multidimensional nmr employing pulsed-field gradients","volume":"4","author":"Schleucher","year":"1994","journal-title":"J Biomol Nmr"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2001.4538","article-title":"Conformational properties of \u03b1-synuclein in its free and lipid-associated states","volume":"307","author":"Eliezer","year":"2001","journal-title":"J Mol Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m413024200","article-title":"Heat shock protein 70 inhibits \u03b1-synuclein fibril formation via preferential binding to prefibrillar species","volume":"280","author":"Dedmon","year":"2005","journal-title":"J Biol Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/bi901285x","article-title":"On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of \u03b1-synuclein with Congo red and lacmoid","volume":"48","author":"Lendel","year":"2009","journal-title":"Biochemistry-Us"},{"key":"B44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann Neurol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1604645113","article-title":"Mutations associated with familial Parkinson\u2019s disease alter the initiation and amplification steps of alpha-synuclein aggregation","volume":"113","author":"Flagmeier","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2010.04.014","article-title":"Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications","volume":"584","author":"Lofblom","year":"2010","journal-title":"FEBS Lett"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201500405","article-title":"Development of a high affinity Affibody-derived protein against amyloid beta-peptide for future Alzheimer\u2019s disease therapy","volume":"10","author":"De Genst","year":"2015","journal-title":"Biotechnol J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.3390\/ijms21082999","article-title":"An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor","volume":"21","author":"Meister","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1574755\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T05:20:15Z","timestamp":1747372815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1574755\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2025.1574755"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1574755","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"article-number":"1574755"}}